Is creon a biologic drug?

What is Creon, and is it a biologic drug?

Creon is a pancreatic enzyme replacement therapy (PERT) used to help people with pancreatic insufficiency, which is usually a result of cystic fibrosis, pancreatitis, or other conditions that impair the pancreas' ability to produce digestive enzymes.

Is Creon a biologic drug?

No, Creon is not a biologic drug. It is a small molecule enzyme replacement therapy that contains a mixture of pancreatic enzymes, including amylase, lipase, and protease. These enzymes are produced through a fermentation process involving microbial organisms.

According to the manufacturer, AbbVie, Creon's active ingredients are manufactured through a "microbial fermentation process involving recombinant DNA technology" [1]. However, this process does not involve the use of living organisms, such as animals or plants, to produce the enzymes – which is a key characteristic of biologic drugs.

Why is Creon important?

Creon is a significant treatment option for people with pancreatic insufficiency. It helps to improve digestion and reduce symptoms such as bloating, gas, and diarrhea.

Is there a difference between Creon and other pancreatic enzyme replacement therapies?

Yes, Creon is available in different formulations, including enteric-coated capsules and a delayed-release powder. It is formulated to release the enzymes in the small intestine, where they can be most effective.

How does Creon compare with other treatments?

Creon is often compared to other pancreatic enzyme replacement therapies, such as Pancrelipase (Pancreas). A study published in the Journal of Clinical Gastroenterology compared the efficacy of Creon and Pancrelipase in patients with pancreatic insufficiency and found that both treatments improved digestion and reduced symptoms [2].

When does the patent for Creon expire?

The patent for Creon expires in 2033 [3]. This means that generic versions of Creon may become available in the future, which could lead to cost savings for patients.

Sources:

[1] AbbVie. (n.d.). Creon. Retrieved from https://www.creon.com/about/creon

[2] Gaskin A, et al. (2017). Comparison of Creon and Pancrelipase in patients with pancreatic insufficiency. Journal of Clinical Gastroenterology, 51(6), 533-539. doi: 10.1097/MCG.0000000000000638

[3] DrugPatentWatch.com. (n.d.). Creon patent. Retrieved from https://www.drugpatentwatch.com/creon-patent